title: Evaluation of safety and efficacy of tivantinib in the treatment of inoperable or recurrent non-small-cell lung cancer.
abstract: Tivantinib is a selective, oral, non-ATP-competitive, small molecule inhibitor of the c-Met receptor, tyrosine kinase, which is implicated at different levels of tumor cell migration, invasion, proliferation, and metastasis. Tivantinib has shown antitumor activity in various human tumor cell lines and in xenograft models of human cancers, including non-small-cell lung cancer. Few therapeutic options are available at present for advanced non-small-cell lung cancer, so there is a pressing need for new therapeutic strategies to improve response and survival. Amplification of Met has been reported in more than 20% of lung tumors that have acquired resistance to epidermal growth factor receptor inhibitors, implying that treatment of these tumors with a c-Met inhibitor should overcome resistance. Tivantinib has shown interesting and promising results in advanced non-small-cell lung cancer and appears to be well tolerated, either alone or in combination with other drugs. An interesting additional feature is the ability of the drug to delay development of new metastasis, in agreement with the proposed role of Met in this particular setting.
authors: Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
authors: Massimo
authors: M
authors: Broggini
authors: Marina Chiara
authors: MC
authors: Garassino
authors: Giovanna
authors: G
authors: Damia
keywords: Met inhibitors; biomarkers; non-small-cell lung cancer; tivantinib
references: Cancer Res. 2005 Feb 15;65(4):1479-88
references: 15735036
references: Clin Lung Cancer. 2012 Sep;13(5):391-5
references: 22440336
references: N Engl J Med. 2010 Jun 24;362(25):2380-8
references: 20573926
references: Cancer Res. 2011 Sep 15;71(18):6051-60
references: 21791641
references: Lung Cancer. 2012 Sep;77(3):507-14
references: 22705117
references: N Engl J Med. 2010 Oct 28;363(18):1734-9
references: 20979473
references: N Engl J Med. 2005 Feb 24;352(8):786-92
references: 15728811
references: Cancer Res. 2008 Jun 1;68(11):4360-8
references: 18519697
references: Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
references: 18093943
references: J Clin Oncol. 2008 Jul 20;26(21):3543-51
references: 18506025
references: Science. 2007 May 18;316(5827):1039-43
references: 17463250
references: PLoS Med. 2005 Mar;2(3):e73
references: 15737014
references: J Clin Oncol. 2011 Aug 20;29(24):3307-15
references: 21768463
references: N Engl J Med. 2009 Sep 3;361(10):947-57
references: 19692680
references: N Engl J Med. 2005 Jul 14;353(2):123-32
references: 16014882
references: Expert Opin Investig Drugs. 2010 Nov;19(11):1381-94
references: 20868306
references: Lung Cancer. 2010 Sep;69(3):272-8
references: 20022659
references: Mol Cancer Ther. 2012 Jan;11(1):214-23
references: 22027690
references: Nat Rev Mol Cell Biol. 2010 Dec;11(12):834-48
references: 21102609
references: Lancet Oncol. 2011 Aug;12(8):735-42
references: 21783417
references: Int J Cancer. 2010 Dec 15;127(12):2893-917
references: 21351269
references: Ann Oncol. 2013 Jan;24(1):14-20
references: 23110808
references: Genes Chromosomes Cancer. 2008 Dec;47(12):1025-37
references: 18709663
references: J Clin Oncol. 2011 Apr 1;29(10):1271-9
references: 21383285
references: Lung Cancer. 2012 Oct;78(1):81-6
references: 22770374
references: J Biol Chem. 2011 Jun 10;286(23):20666-76
references: 21454604
references: Mol Cancer Ther. 2010 Jun;9(6):1544-53
references: 20484018
references: Cancer. 2012 Dec 1;118(23):5903-11
references: 22605616
references: N Engl J Med. 2010 Oct 28;363(18):1693-703
references: 20979469